Biopharma was Pfizer’s largest segment in fiscal 2025, bringing in $61.20B of $62.58B (98%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharma | $99.83B | $58.24B | $62.40B | $61.20B | ||||||||||||
| Innovative Health & Essential Health | — | — | — | — | ||||||||||||
| Innovative Health | — | — | — | — | ||||||||||||
| Global Established Pharmaceutical | — | — | — | — | ||||||||||||
| Essential Health | — | — | — | — | ||||||||||||
| Primary Care | — | — | — | — | ||||||||||||
| Established Products & Emerging Markets | — | — | — | — | ||||||||||||
| Specialty Care & Oncology | — | — | — | — | ||||||||||||
| Global Innovative Pharmaceutical | — | — | — | — | ||||||||||||
| Upjohn | — | — | — | — | ||||||||||||
| Global Vaccines, Oncology & Consumer Healthcare | — | — | — | — | ||||||||||||
| Other Operating Segments | — | — | — | — | ||||||||||||
| Segment Reconciling Items | — | — | — | — | ||||||||||||
| Other Operating Segment & Other Business Activities | — | — | — | — | ||||||||||||
| Animal Health & Consumer Healthcare Operating Segment | — | — | — | — | ||||||||||||
| Business Innovation | — | — | — | — | ||||||||||||
| Other Business Activities | $1.35B | $1.32B | $1.23B | $1.38B | ||||||||||||
| Corporate, Non-Segment | — | — | — | — | ||||||||||||
| Pc1 | — | — | — | — | ||||||||||||
| Nutrition & Other Business Activities | — | — | — | — | ||||||||||||
| Certain Significant Items | — | — | — | — | ||||||||||||
| Total | $101.18B | $59.55B | $63.63B | $62.58B |
Pfizer brought in $62.58B from its two segments in fiscal 2025, the year ended December 31, 2025. That was down 1.6% from $63.63B in fiscal 2024. Biopharma was the largest at $61.20B (97.8%), ahead of Other Business Activities at $1.38B (2.2%).
Compared with fiscal 2024, Other Business Activities grew 12.4% to $1.38B, while Biopharma fell 1.9% to $61.20B. From fiscal 2022 to 2025, combined revenue from these segments fell from $101.18B to $62.58B, a compound annual decline of 14.8%. Biopharma's share of the total fell from 98.7% to 97.8%.
U.S was Pfizer’s largest region in fiscal 2025, bringing in $37.08B of $62.58B (59%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S | $43.32B | $28.15B | $38.69B | $37.08B | |||||||||||||
| Us | — | — | — | — | |||||||||||||
| United States | — | — | — | — | |||||||||||||
| United States [Member} | — | — | — | — | |||||||||||||
| Developed Markets | $40.53B | $20.91B | $16.06B | $16.19B | |||||||||||||
| Emerging Markets | $17.32B | $10.50B | $8.88B | $9.31B | |||||||||||||
| Developed Europe | — | — | — | — | |||||||||||||
| Developed Rest Of World | — | — | — | — | |||||||||||||
| Total | $101.18B | $59.55B | $63.63B | $62.58B |
Pfizer brought in $62.58B from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 1.6% from $63.63B in fiscal 2024. U.S was the largest at $37.08B (59.2%), ahead of Developed Markets at $16.19B (25.9%) and Emerging Markets at $9.31B (14.9%).
Compared with fiscal 2024, Emerging Markets grew fastest, up 4.9% to $9.31B, while U.S fell the most, down 4.2% to $37.08B. From fiscal 2022 to 2025, combined revenue from these regions fell from $101.18B to $62.58B, a compound annual decline of 14.8%. U.S's share of the total rose from 42.8% to 59.2%.
Primary Care was Pfizer’s largest revenue line in fiscal 2024, bringing in $30.14B of $62.40B (48%).
| Reporting Unit | FY 2017 | FY 2018 | FY 2019 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|
| Primary Care | $73.18B | $30.80B | $30.14B | |||
| Specialty Care | $13.85B | $14.99B | $16.65B | |||
| Upjohn Reporting Unit | — | — | — | |||
| Oncology | $12.79B | $12.45B | $15.61B | |||
| Internal Medicine | — | — | — | |||
| Hospital | — | — | — | |||
| Vaccines | — | — | — | |||
| Inflammation & Immunology | — | — | — | |||
| Consumer Healthcare Reporting Unit | — | — | — | |||
| Rare Disease | — | — | — | |||
| Total | $99.83B | $58.24B | $62.40B |
Pfizer brought in $62.40B from its three revenue lines in fiscal 2024, the year ended December 31, 2024. That was up 7.1% from $58.24B in fiscal 2023. Primary Care was the largest at $30.14B (48.3%), ahead of Specialty Care at $16.65B (26.7%) and Oncology at $15.61B (25.0%).
Compared with fiscal 2023, Oncology grew fastest, up 25.4% to $15.61B, while Primary Care fell the most, down 2.2% to $30.14B. From fiscal 2022 to 2024, combined revenue from these revenue lines fell from $99.83B to $62.40B, a compound annual decline of 20.9%. Primary Care's share of the total fell from 73.3% to 48.3%.
Pfizer (PFE) reports its revenue by segment, by geography and by reporting unit. In fiscal 2025, Biopharma was its largest segment, bringing in $61.20B (97.8% of the total), followed by Other Business Activities at $1.38B (2.2%).
Biopharma was Pfizer's largest segment in fiscal 2025, bringing in $61.20B, or 97.8% of the $62.58B total across its two segments.
U.S was Pfizer's largest region in fiscal 2025, bringing in $37.08B, or 59.2% of the $62.58B total across its three regions.
Primary Care was Pfizer's largest revenue line in fiscal 2024, bringing in $30.14B, or 48.3% of the $62.40B total across its three revenue lines.
Other Business Activities grew faster than Biopharma in fiscal 2025, up 12.4% from $1.23B to $1.38B. Biopharma fell 1.9% to $61.20B.
Every figure comes from Pfizer's annual financial filings, as reported. Each line keeps the name Pfizer gives it, and years follow its fiscal calendar.
Pfizer's revenue by segment goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.